Xcout Intel
Gibson Oncology, LLC competitors & alternatives
The 12 closest competitors and alternatives to Gibson Oncology, LLC among biotechnology companies — ranked by similarity to what Gibson Oncology, LLC actually does, not by market-cap band.
Subscribe to see Gibson Oncology, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Gibson Oncology, LLC
Gibson Oncology is a biopharmaceutical company that develops treatments for brain cancer, focusing on its lead program involving the drug LMP744 for recurrent glioblastoma. The company is advancing LMP744 through clinical trials, including an NIH-conducted phase II trial for patients who have failed initial therapy.
Gibson Oncology, LLC at a glance
Gibson Oncology, LLC is a biotechnology company headquartered in United States. It has raised at least $4M across the 2 funding rounds on record. Its most recent funding round raised $250,000 in July 2025. Xcout tracks 8 named people at Gibson Oncology, LLC, including Randall Riggs (Chief Executive Officer).
Gibson Oncology, LLC leadership
- Randall RiggsChief Executive Officer
- Clifford SolomonExecutive Officer
- Elizabeth RogersExecutive Officer
- Randall RiggsExecutive Officer
- Theodore SolomonExecutive Officer
- Mark BaganzDirector
2 more named people on record for Gibson Oncology, LLC, with roles, board committees and tenure — see the full roster →
Gibson Oncology, LLC funding rounds
At least $4M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $250,000 | — | |
| SEC Form D filing | $3.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Gibson Oncology, LLC competitors
Ranked by semantic similarity — how close each company is to Gibson Oncology, LLC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
Similar biotechnology company
Treovir is a clinical-stage biotechnology company that develops therapies for pediatric brain tumors. Its lead product candidate, G207, is an oncolytic virus therapy currently undergoing clinical trials to treat conditions such as pediatric recurrent glioblastoma.
Similar biotechnology company
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.
Biotech
Gate2Brain is a Barcelona-based biotechnology company focused on developing advanced pharmaceutical candidates to cross biological barriers for the treatment of brain tumors.
Similar biotechnology company
Reglagene Holding, Inc. is a biotechnology company developing brain-penetrant oral therapies for central nervous system oncology. Its lead small molecule candidate, RGN6024, is designed to cross the blood-brain barrier and evade efflux pumps to treat primary tumors and brain metastases.
Similar biotechnology company
Altido Therapeutics is a clinical-stage biotechnology company located in Waltham, Massachusetts that is advancing a dual-mechanism CAR-TEAM immunotherapy platform to treat glioblastoma.
Similar biotechnology company
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Biotech
TME Pharma is a clinical-stage biotechnology company that develops novel therapies targeting the tumor microenvironment to treat aggressive cancers such as glioblastoma and pancreatic cancer. Its proprietary technology neutralizes chemokines to break down tumor protection barriers, allowing combination treatments to achieve a greater therapeutic impact.
Biotech
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Similar biotechnology company
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Similar biotechnology company
CVBio is a biotechnology company that develops virus-driven immunotherapies, specifically utilizing engineered oncolytic adenoviruses to target and destroy resistant cancer cells. The company's platform is designed to treat aggressive cancers, including adult and pediatric brain tumors, by selectively infecting tumor cells and eliciting an anti-tumor immune response.
Biotech
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Gibson Oncology, LLC and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Gibson Oncology, LLCand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →